CertainT-1

Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
18 patients (estimated)
Tags
Chimeric Engulfment Receptor T-cell (CER-T), TIM-4
Trial Type
Treatment
Last Update
SparkCures ID
2261
NCT Identifier
NCT06834282

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.